The Massachusetts company has reported the results of the phase 3 MAESTRO-NASH trial of resmetirom – a once daily, oral, thyroid hormone receptor (THR) β-selective agonist – showing that it ...

Resmetirom's FDA approval offers a liver-specific therapy, reducing hepatic fat and fibrosis, potentially improving patient outcomes and lowering care costs. Resmetirom offers a targeted approach ...

Its lead candidate resmetirom met its primary and secondary objectives in the trial, which involved patients with non-alcoholic fatty liver disease (NAFLD) including some with presumed NASH ...